Trials / Unknown
UnknownNCT05067959
Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 284 (actual)
- Sponsor
- Rabin Medical Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The 2019-coronavirus disease (COVID-19), caused by SARS-CoV-2, was identified as the source of pneumonia cases in Wuhan city in China. It rapidly spread worldwide and was declared by WHO as a pandemic. COVID-19 vaccines are expected to be the breakthrough in controlling the pandemic. However, studies performed only in healthy adults, and specifically excluded patients who were under immunomodulatory/biologic therapy, thus excluding patients with chronic inflammatory diseases (IBD). In this study we wish to understand vaccine efficacy and immunological response in IBD patients.
Detailed description
Overall Aims: 1. To assess the immune response to COVID-19 vaccination in patients with IBD. 2. Comparing the short and long term immune response to vaccination among subgroups receiving different therapies. 3. To evaluate the different variables affecting immunity of these patients. 4. To assess adverse reactions to COVID-19 vaccines and IBD related complications. Specifically: 1. To assess serologic response to COVID-19 vaccine(s) in patients with IBD treated with anti-TNF agents (+/- immunomodulators) compared to 1. Healthy controls 2. Patients with IBD not treated with anti-TNF (+/- immunomodulators) 2. To characterize serologic response: seroconversion, seroprotection and persistence of COVID-19 vaccine(s) in patients with IBD 3. To identify factors associated with serologic response 4. Side effects to vaccines 5. IBD exacerbation compared to activity at baseline 6. Symptomatic COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Covid-19 vaccine | blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine |
Timeline
- Start date
- 2020-12-28
- Primary completion
- 2021-12-01
- Completion
- 2022-03-01
- First posted
- 2021-10-05
- Last updated
- 2021-10-05
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT05067959. Inclusion in this directory is not an endorsement.